The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
Featured:
María-Victoria MateosMultiple Myeloma Hub Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, provided the Multiple Myeloma Hub with updates from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress. We asked, CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
Significant improvements in both the diagnosis and treatment of MM have been observed in recent years. Despite this, MM remains an incurable disease and patients eventually relapse or become refractory to treatment. CAR T-cell therapy and bispecific T-cell engager monoclonal antibodies have demonstrated promising results in this setting. Here, María-Victoria Mateos outlines the major factors for consideration when choosing a patient's treatment course with such agents.